212 related articles for article (PubMed ID: 37963879)
1. Targeted suppression of mTORC2 reduces seizures across models of epilepsy.
Okoh J; Mays J; Bacq A; Oses-Prieto JA; Tyanova S; Chen CJ; Imanbeyev K; Doladilhe M; Zhou H; Jafar-Nejad P; Burlingame A; Noebels J; Baulac S; Costa-Mattioli M
Nat Commun; 2023 Nov; 14(1):7364. PubMed ID: 37963879
[TBL] [Abstract][Full Text] [Related]
2. mTORC2 Inhibition Improves Morphological Effects of PTEN Loss, But Does Not Correct Synaptic Dysfunction or Prevent Seizures.
Cullen ER; Tariq K; Shore AN; Luikart BW; Weston MC
J Neurosci; 2023 Feb; 43(5):827-845. PubMed ID: 36526374
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic inhibition of mTORC2 rescues the behavioral and neurophysiological abnormalities associated with Pten-deficiency.
Chen CJ; Sgritta M; Mays J; Zhou H; Lucero R; Park J; Wang IC; Park JH; Kaipparettu BA; Stoica L; Jafar-Nejad P; Rigo F; Chin J; Noebels JL; Costa-Mattioli M
Nat Med; 2019 Nov; 25(11):1684-1690. PubMed ID: 31636454
[TBL] [Abstract][Full Text] [Related]
4. mTOR inhibition suppresses established epilepsy in a mouse model of cortical dysplasia.
Nguyen LH; Brewster AL; Clark ME; Regnier-Golanov A; Sunnen CN; Patil VV; D'Arcangelo G; Anderson AE
Epilepsia; 2015 Apr; 56(4):636-46. PubMed ID: 25752454
[TBL] [Abstract][Full Text] [Related]
5. Hyperactivity of mTORC1- and mTORC2-dependent signaling mediates epilepsy downstream of somatic PTEN loss.
Cullen ER; Safari M; Mittelstadt I; Weston MC
Elife; 2024 Mar; 12():. PubMed ID: 38446016
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of mTORC2 improves brain injury in epileptic rats by promoting chaperone-mediated autophagy.
Zhao Y; Zhao W; Han Y
Epilepsy Res; 2023 Jul; 193():107161. PubMed ID: 37163909
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage.
Völkers M; Konstandin MH; Doroudgar S; Toko H; Quijada P; Din S; Joyo A; Ornelas L; Samse K; Thuerauf DJ; Gude N; Glembotski CC; Sussman MA
Circulation; 2013 Nov; 128(19):2132-44. PubMed ID: 24008870
[TBL] [Abstract][Full Text] [Related]
8. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic target of rapamycin complex 1 and 2 in human temporal lobe epilepsy.
Talos DM; Jacobs LM; Gourmaud S; Coto CA; Sun H; Lim KC; Lucas TH; Davis KA; Martinez-Lage M; Jensen FE
Ann Neurol; 2018 Feb; 83(2):311-327. PubMed ID: 29331082
[TBL] [Abstract][Full Text] [Related]
10. Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma.
Jhanwar-Uniyal M; Dominguez JF; Mohan AL; Tobias ME; Gandhi CD
Adv Biol Regul; 2022 Jan; 83():100854. PubMed ID: 34996736
[TBL] [Abstract][Full Text] [Related]
11. Raptor downregulation rescues neuronal phenotypes in mouse models of Tuberous Sclerosis Complex.
Karalis V; Caval-Holme F; Bateup HS
Nat Commun; 2022 Aug; 13(1):4665. PubMed ID: 35945201
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of mTORC1/2 or PI3K/mTORC1/2 signaling does not prevent or modify epilepsy in the intrahippocampal kainate mouse model.
Gericke B; Brandt C; Theilmann W; Welzel L; Schidlitzki A; Twele F; Kaczmarek E; Anjum M; Hillmann P; Löscher W
Neuropharmacology; 2020 Jan; 162():107817. PubMed ID: 31654704
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy.
Huang X; Zhang H; Yang J; Wu J; McMahon J; Lin Y; Cao Z; Gruenthal M; Huang Y
Neurobiol Dis; 2010 Oct; 40(1):193-9. PubMed ID: 20566381
[TBL] [Abstract][Full Text] [Related]
14. Dengue activates mTORC2 signaling to counteract apoptosis and maximize viral replication.
Carter CC; Mast FD; Olivier JP; Bourgeois NM; Kaushansky A; Aitchison JD
Front Cell Infect Microbiol; 2022; 12():979996. PubMed ID: 36171757
[TBL] [Abstract][Full Text] [Related]
15. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.
Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG
PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809
[TBL] [Abstract][Full Text] [Related]
16. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
Feldman ME; Apsel B; Uotila A; Loewith R; Knight ZA; Ruggero D; Shokat KM
PLoS Biol; 2009 Feb; 7(2):e38. PubMed ID: 19209957
[TBL] [Abstract][Full Text] [Related]
17. mTORC1 and mTORC2 regulate skin morphogenesis and epidermal barrier formation.
Ding X; Bloch W; Iden S; Rüegg MA; Hall MN; Leptin M; Partridge L; Eming SA
Nat Commun; 2016 Oct; 7():13226. PubMed ID: 27807348
[TBL] [Abstract][Full Text] [Related]
18. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
Weinberg MA
Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
[TBL] [Abstract][Full Text] [Related]
19. TRAF2 and OTUD7B govern a ubiquitin-dependent switch that regulates mTORC2 signalling.
Wang B; Jie Z; Joo D; Ordureau A; Liu P; Gan W; Guo J; Zhang J; North BJ; Dai X; Cheng X; Bian X; Zhang L; Harper JW; Sun SC; Wei W
Nature; 2017 May; 545(7654):365-369. PubMed ID: 28489822
[TBL] [Abstract][Full Text] [Related]
20. Prevention of premature death and seizures in a Depdc5 mouse epilepsy model through inhibition of mTORC1.
Klofas LK; Short BP; Zhou C; Carson RP
Hum Mol Genet; 2020 May; 29(8):1365-1377. PubMed ID: 32280987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
